Breakthrough Research Unlocks Nature's Blueprint for Better Cancer Drug Discovery

Scientists have finally cracked a decades-old mystery of how bacteria naturally produce multiple cancer-fighting drugs-a breakthrough that could accelerate the development of more effective and targeted cancer therapies.

In a study published in Nature Communications, researchers uncovered how bacteria assemble different versions of powerful anti-cancer compounds. The discovery reveals the molecular mechanism behind a natural process known as combinatorial biosynthesis, which scientists have long hoped to harness for designing new medicines.

The team found that tiny molecular regions called docking domains act as connectors between two separate enzyme systems. One enzyme complex builds the core drug structure, while another adds variable chemical "caps" that determine the drug's cancer-targeting properties. These docking domains function like molecular puzzle pieces, allowing enzymes to communicate precisely and generate multiple drug variants without compromising their effectiveness.

Researchers say this flexible yet highly organized system explains how bacteria naturally create families of closely related anti-cancer molecules. The study also suggests these pathways evolved through gene duplication and recombination, enabling bacteria to diversify their chemical arsenal over time.

The discovery also solves the long-standing mystery of how bacteria produce FR-901375, a compound whose biosynthetic pathway had remained unknown for decades. Both belong to the HDAC inhibitor class of drugs, which work by blocking histone deacetylases—enzymes involved in regulating gene activity in cancer cells.

Researchers believe the findings provide a blueprint for engineering synthetic biosynthetic pathways capable of producing entirely new anti-cancer drug candidates with greater potency, improved selectivity, and fewer side effects. The approach could expand treatment options for cancers that remain difficult to manage with current therapies.

REFERENCE: Munro Passmore, Xinyun Jian, Xinyi Zhao, Emmanuel L. C. de los Santos, Douglas M. Roberts, Józef R. Lewandowski, Matthew Jenner, Lona M. Alkhalaf, Gregory L. Challis. Molecular basis for depsipeptide HDAC inhibitor combinatorial biosynthesis. Nature Communications, 2026; 17 (1) DOI: 10.1038/s41467-026-74383-4